We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

152 hedge funds and large institutions have $369M invested in Aquestive Therapeutics in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

336% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 11

134% more capital invested

Capital invested by funds: $158M → $369M (+$212M)

121% more call options, than puts

Call options by funds: $7.07M | Put options by funds: $3.21M

63% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 32

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

31% more funds holding

Funds holding: 116 → 152 (+36)

18.29% more ownership

Funds ownership: 47.95% → 66.24% (+18%)

Holders
152
Holders Change
+36
Holders Change %
+31.03%
% of All Funds
1.99%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
48
Increased
52
Reduced
32
Closed
11
Calls
$7.07M
Puts
$3.21M
Net Calls
+$3.86M
Net Calls Change
+$4.3M

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$27M
2
EC
EcoR1 Capital
California
+$11.3M
3
SB
Samsara BioCapital
California
+$10.8M
4
PA
Perceptive Advisors
New York
+$6.79M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.77M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$7.31M
2
PFCS
Pale Fire Capital SE
Czech Republic
-$6.85M
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$1.83M
4
WP
Woodline Partners
California
-$1.35M
5
EAM
Everstar Asset Management
North Carolina
-$1.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$2.87M +$1.6M +370,589 +261%
Walleye Capital
27
Walleye Capital
New York
$2.82M +$1.16M +267,370 +112%
UBS Group
28
UBS Group
Switzerland
$2.79M +$596K +137,772 +38%
JP Morgan Chase
29
JP Morgan Chase
New York
$2.65M +$163K +37,607 +9%
BCL
30
Bracebridge Capital LLC
Massachusetts
$2.57M – – –
Goldman Sachs
31
Goldman Sachs
New York
$2.21M -$560K -129,535 -25%
Marshall Wace
32
Marshall Wace
United Kingdom
$2.07M +$1.29M +298,487 +411%
EAM
33
Everstar Asset Management
North Carolina
$2.06M -$1.26M -290,318 -44%
Stifel Financial
34
Stifel Financial
Missouri
$2.05M -$33.7K -7,800 -2%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$2.03M +$95.1K +21,985 +6%
HCM
36
Harvey Capital Management
Florida
$1.92M +$43.2K +10,000 +3%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.6M +$175K +40,478 +17%
Charles Schwab
38
Charles Schwab
California
$1.42M +$42.3K +9,775 +4%
LI
39
Latash Investments
Alaska
$1.36M – – –
GCP
40
GSA Capital Partners
United Kingdom
$1.35M +$236K +54,667 +29%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.16M +$96.5K +22,323 +12%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$913K +$154K +35,681 +28%
EI
43
EAM Investors
California
$852K +$659K +152,332 New
Osaic Holdings
44
Osaic Holdings
Arizona
$818K -$128K -29,636 -17%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$816K +$631K +146,022 New
Creative Planning
46
Creative Planning
Kansas
$809K +$199K +45,910 +46%
DC
47
Diametric Capital
Massachusetts
$777K -$114K -26,301 -16%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$752K -$27.7K -6,402 -5%
Barclays
49
Barclays
United Kingdom
$737K -$95.4K -22,070 -14%
Wells Fargo
50
Wells Fargo
California
$734K +$121K +27,955 +27%
1
2
3 4 5

AQST Hedge Fund Activity: Q3 2025 in Review

152 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2025, worth a combined $369M — up 134% from $158M a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new AQST positions and 11 closed out — a net gain of 37 holders — while 52 added to existing stakes and 32 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $27M. The largest seller was Millennium Management, cutting an estimated $7.31M.

  • 152 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2025, up from 116 in Q2 2025.
  • Funds reported $369M of Aquestive Therapeutics stock for Q3 2025, up 134% quarter-over-quarter.
  • 48 funds opened new Aquestive Therapeutics positions in Q3 2025 and 11 closed out, a net change of +37 holders.
  • The largest Aquestive Therapeutics buyer in Q3 2025 was RTW Investments, an estimated $27M added.
  • The largest Aquestive Therapeutics seller in Q3 2025 was Millennium Management, an estimated $7.31M sold.

Based on aggregated 13F filings for Q3 2025.